Sebitchem's annual results have shown pronounced swings.
After peaking in 2022 with revenue of KRW 48.1 billion, operating profit of KRW 10.2 billion (operating margin of 21.2%), and net profit of KRW 7.7 billion, the company swung to an operating loss of KRW 4.9 billion (operating margin of -10.7%) on revenue of KRW 46.0 billion in 2023.
In 2024, revenue fell to KRW 30.3 billion while the operating loss widened to KRW 6.2 billion (-20.3%), and in 2025 revenue recovered somewhat to KRW 38.4 billion, but the operating loss grew to KRW 9.4 billion (-24.5%) and the net loss expanded to KRW 18.0 billion, marking a fourth consecutive year of net losses.
Owner's equity fell from KRW 63.1 billion in 2022 to KRW 45.4 billion in 2025, while the debt ratio jumped from 41.9% to 82.4% over the same period.
On a quarterly basis, the loss was widest in Q3 2025 with revenue of KRW 7.2 billion and an operating loss of KRW 3.1 billion, followed by a Q4 net loss that surged to KRW 10.4 billion despite revenue of KRW 10.5 billion, suggesting a one-off factor.
The loss then narrowed sharply in Q1 2026 to an operating loss of KRW 0.5 billion on revenue of KRW 13.5 billion, and in Q2 2026 the company posted revenue of KRW 17.4 billion, operating profit of KRW 0.9 billion, and net profit of KRW 0.8 billion, its first quarterly profit swing in three years.
However, the trailing four-quarter net result (Q3 2025 through Q2 2026) still totals a loss of KRW 12.9 billion, meaning additional quarters are needed to confirm whether the Q2 turnaround reflects a structural improvement.
Operating cash flow in 2025 was negative KRW 12.6 billion, a sharp reversal from positive KRW 1.0 billion in 2024, indicating expanded funding needs even as the profit and loss picture began to improve.